Niagen Bioscience (NAGE) Net Income towards Common Stockholders (2010 - 2026)

Niagen Bioscience (NAGE) has reported Net Income towards Common Stockholders for 16 consecutive years, with $6.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 24.79% year-over-year to $6.3 million; the TTM figure through Mar 2026 stood at $18.6 million (up 32.13% YoY), while the FY2025 annual figure was $17.4 million, up 103.3% from the prior year.
• Net Income towards Common Stockholders rose to $6.3 million in Q1 2026 per NAGE's latest filing, from $4.1 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $7.2 million in Q4 2024 and bottomed at -$11.7 million in Q2 2022.
• Historically, Net Income towards Common Stockholders has averaged -$968352.9 across 5 years, with a median of -$270000.0 in 2023.
• On a YoY basis, Net Income towards Common Stockholders climbed as much as 24160.0% in 2025 and fell as far as 42.44% in 2025.
• Niagen Bioscience's Net Income towards Common Stockholders stood at -$1.6 million in 2022, then surged by 82.9% to -$270000.0 in 2023, then jumped by 2758.89% to $7.2 million in 2024, then sank by 42.44% to $4.1 million in 2025, then jumped by 52.9% to $6.3 million in 2026.
• Business Quant data shows NAGE's Net Income towards Common Stockholders at $6.3 million in Q1 2026, $4.1 million in Q4 2025, and $4.6 million in Q3 2025.